Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) has received a consensus recommendation of “Buy” from the ...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...

Shares of Catalyst Pharmaceuticals Inc. CPRX slipped 3.27% to $19.53 Tuesday, on what proved to be an all-around rough ...